XOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks Research

Key Points

• XOMA Royalty has been upgraded to a "hold" rating by Zacks Research, amidst recent assessments from other analysts indicating varying degrees of optimism about the stock.
• Benchmark has set a target price of $35.00 while HC Wainwright estimates the price at $104.00, indicating a potential for significant price appreciation.
• The company reported an earnings per share (EPS) of $0.48 for the last quarter, surpassing expectations and generating revenue of $13.13 million, which also exceeded analyst projections.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) was upgraded by research analysts at Zacks Research to a "hold" rating in a research note issued on Tuesday,Zacks.com reports.

Several other research analysts also recently commented on XOMA. Benchmark initiated coverage on XOMA Royalty in a research note on Thursday, April 17th. They set a "buy" rating and a $35.00 target price for the company. HC Wainwright restated a "buy" rating and set a $104.00 price objective on shares of XOMA Royalty in a research report on Wednesday, May 28th. Finally, Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday.

XOMA Royalty Stock Performance

NASDAQ XOMA traded up $0.28 during trading on Tuesday, hitting $31.87. The company's stock had a trading volume of 7,798 shares, compared to its average volume of 43,261. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. The firm has a 50 day moving average price of $26.28 and a 200 day moving average price of $24.31. The firm has a market cap of $381.47 million, a P/E ratio of -20.45 and a beta of 1.00. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $35.00.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a positive return on equity of 2.54% and a negative net margin of 27.57%. The business had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million. Equities research analysts forecast that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other XOMA Royalty news, CEO Owen Hughes sold 25,637 shares of the company's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the transaction, the chief executive officer directly owned 62,701 shares in the company, valued at $1,591,351.38. This represents a 29.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On XOMA Royalty

Several institutional investors and hedge funds have recently bought and sold shares of the business. Nuveen Asset Management LLC lifted its position in XOMA Royalty by 3.8% during the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company's stock valued at $377,000 after purchasing an additional 527 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 543 shares during the period. Eversept Partners LP lifted its holdings in XOMA Royalty by 1.2% during the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock worth $2,508,000 after buying an additional 1,128 shares during the period. Wells Fargo & Company MN increased its position in shares of XOMA Royalty by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 1,183 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of XOMA Royalty by 1.5% during the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock worth $2,396,000 after purchasing an additional 1,340 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.